HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on Relay Therapeutics (NASDAQ:RLAY) but has lowered the price target from $33 to $19.
November 08, 2023 | 4:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Relay Therapeutics' price target has been lowered from $33 to $19 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. indicates a potential decrease in the short-term value of Relay Therapeutics' stock. However, the maintained 'Buy' rating suggests that the company is still viewed favorably for long-term investment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100